$IMCR

Immunocore Holdings plc

Immunocore is a commercial-stage biotechnology company that develops immunomodulating medicines for cancer, infectious diseases and autoimmune diseases. Its ImmTAX platform produces off-the-shelf bispecific therapeutics that pair engineered T-cell receptors with immune-modulating effector functions. Its product platforms include ImmTAC for cancer, ImmTAV for viral diseases and ImmTAAI for autoimmune conditions. Immunocore’s first approved product, KIMMTRAK, treats eligible adults with unresectable or metastatic uveal melanoma. It is approved in 39 countries and launched in 30, including the United States. The company also develops candidates including brenetafusp for cancer, IMC-M113V for HIV and candidates for autoimmune diseases. Immunocore sells KIMMTRAK directly through an in-house U.S. sales force and uses contracted commercial resources and regional distribution partners in the United States, Europe and other territories. It is headquartered in Oxfordshire, United Kingdom.

1
1
0

No SEC Form 4 filings for $IMCR in the last 30 days.

See all $IMCR insider activity →
Low

Baird reiterates Immunocore stock rating on combination therapy data

Baird maintained an Outperform rating and $84.00 price target for Immunocore (IMCR), citing positive Phase 1/2 data for a combination therapy in uveal melanoma. The stock trades at $29.13, with analysts noting potential undervaluation. IMCR reported $429M revenue over the last year, with 13% growth but no profitability. Five analysts revised earnings upwards.

IMCR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IMCR (Immunocore Holdings plc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent IMCR coverage spans financial news, earnings and corporate actions.

What's driving IMCR

  • Analyst stance is bullish on combination-therapy durability, supporting a positive risk/reward narrative for IMCR tied to melanoma penetration and durability.

    investing.com · Nov 16, 2026

  • The analyst action is mildly bearish via a lower price target, but the rating is unchanged (Equal-Weight).

    tradingview.com · Nov 13, 2026

  • HC Wainwright & Co. kept its Buy rating on Immunocore Holdings but reduced its price target to $80 from $100, a 20% cut. This implies a 152.1% upside from the Nov 9 closing price of $31.73, according to the firm.

    tradingview.com · Nov 10, 2026

  • Positive early‑stage trial results suggest significant clinical benefit, likely boosting investor sentiment.

    stocktitan.net · Nov 6, 2026

  • Earnings miss likely pressures the stock lower.

    tradingview.com · Nov 6, 2026

AlphAI scores every news story that mentions IMCR with an AI model for sentiment and relevance, and aggregates insider trades from Immunocore Holdings plc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMCR

Score

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.

$IMCRMedAI 8/10Clinical / regulatory

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Regulation FD Disclosure. Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US,

Immunocore Q2 Earnings Call Highlights

Immunocore (NASDAQ:IMCR) reported Q2 updates on tebentafusp (KIMMTRAK). At AACR, it cited 5-year overall survival of 16% vs 8% in HLA-A*02:01-positive metastatic uveal melanoma. TEBE-AM enrollment nears 540; topline data expected end-2026. Q2 R&D was $74M, net loss just under $1M, cash $880M. Rebates expected ~$120M in H2 2026.

$IMCRMedEarnings

Immunocore reports second quarter financial results and provides a business update

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing

Related tickers